ASX - By Stock
|
RAP |
Re:
The End of Such Hope and Promise
|
|
TheSanDiegoKid
|
18 |
6.8K |
19 |
15/09/22 |
15/09/22 |
ASX - By Stock
|
18
|
6.8K
|
19
|
|
ASX - By Stock
|
PCK |
Re:
Ann: Financial Statements 30 June 2022 & Appendix 4E
|
|
TheSanDiegoKid
|
233 |
59K |
5 |
12/09/22 |
12/09/22 |
ASX - By Stock
|
233
|
59K
|
5
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results of Scheme Meeting
|
|
TheSanDiegoKid
|
250 |
83K |
43 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
250
|
83K
|
43
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Becoming a substantial holder
|
|
TheSanDiegoKid
|
93 |
36K |
6 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
93
|
36K
|
6
|
|
ASX - By Stock
|
RAP |
Re:
I'm getting out, good luck gents
|
|
TheSanDiegoKid
|
195 |
71K |
2 |
06/09/22 |
06/09/22 |
ASX - By Stock
|
195
|
71K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Second Supplementary Scheme Booklet
|
|
TheSanDiegoKid
|
255 |
72K |
25 |
25/08/22 |
25/08/22 |
ASX - By Stock
|
255
|
72K
|
25
|
|
ASX - By Stock
|
RAP |
Re:
Why you should vote NO from a non professional investor
|
|
TheSanDiegoKid
|
35 |
9.5K |
22 |
21/08/22 |
21/08/22 |
ASX - By Stock
|
35
|
9.5K
|
22
|
|
ASX - By Stock
|
RAP |
Re:
Why you should vote NO from a non professional investor
|
|
TheSanDiegoKid
|
35 |
9.5K |
10 |
20/08/22 |
20/08/22 |
ASX - By Stock
|
35
|
9.5K
|
10
|
|
ASX - By Stock
|
RAP |
Re:
Why you should vote YES - a professional investor's perspective
|
|
TheSanDiegoKid
|
208 |
58K |
23 |
18/08/22 |
18/08/22 |
ASX - By Stock
|
208
|
58K
|
23
|
|
ASX - By Stock
|
RAP |
Re:
VOTE NO. AWAIT "BEST & FINAL" DECLARATION
|
|
TheSanDiegoKid
|
313 |
93K |
5 |
11/08/22 |
11/08/22 |
ASX - By Stock
|
313
|
93K
|
5
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Pfizer raises scheme consideration to A$0.208 per share
|
|
TheSanDiegoKid
|
101 |
31K |
43 |
06/08/22 |
06/08/22 |
ASX - By Stock
|
101
|
31K
|
43
|
|
ASX - By Stock
|
RAP |
Re:
Offer Increase 21c Vote Yes
|
|
TheSanDiegoKid
|
252 |
74K |
52 |
04/08/22 |
04/08/22 |
ASX - By Stock
|
252
|
74K
|
52
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Quarterly Activities Report and Appendix 4C
|
|
TheSanDiegoKid
|
62 |
18K |
42 |
27/07/22 |
27/07/22 |
ASX - By Stock
|
62
|
18K
|
42
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Scheme Update
|
|
TheSanDiegoKid
|
132 |
47K |
33 |
01/07/22 |
01/07/22 |
ASX - By Stock
|
132
|
47K
|
33
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResApp to present at Gold Coast Investment Showcase
|
|
TheSanDiegoKid
|
93 |
32K |
35 |
26/06/22 |
26/06/22 |
ASX - By Stock
|
93
|
32K
|
35
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResApp to present at Gold Coast Investment Showcase
|
|
TheSanDiegoKid
|
93 |
32K |
10 |
25/06/22 |
25/06/22 |
ASX - By Stock
|
93
|
32K
|
10
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
TheSanDiegoKid
|
425 |
130K |
8 |
23/06/22 |
23/06/22 |
ASX - By Stock
|
425
|
130K
|
8
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
TheSanDiegoKid
|
425 |
130K |
10 |
22/06/22 |
22/06/22 |
ASX - By Stock
|
425
|
130K
|
10
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
TheSanDiegoKid
|
377 |
145K |
0 |
22/06/22 |
22/06/22 |
ASX - By Stock
|
377
|
145K
|
0
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
TheSanDiegoKid
|
425 |
130K |
1 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
425
|
130K
|
1
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
TheSanDiegoKid
|
425 |
130K |
16 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
425
|
130K
|
16
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
TheSanDiegoKid
|
377 |
145K |
2 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
377
|
145K
|
2
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
TheSanDiegoKid
|
377 |
145K |
0 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
377
|
145K
|
0
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
TheSanDiegoKid
|
377 |
145K |
8 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
377
|
145K
|
8
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
TheSanDiegoKid
|
377 |
145K |
14 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
377
|
145K
|
14
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
TheSanDiegoKid
|
425 |
130K |
24 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
425
|
130K
|
24
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
TheSanDiegoKid
|
425 |
130K |
10 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
425
|
130K
|
10
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
TheSanDiegoKid
|
425 |
130K |
19 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
425
|
130K
|
19
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
TheSanDiegoKid
|
425 |
130K |
19 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
425
|
130K
|
19
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Results from Data Confirmation Study
|
|
TheSanDiegoKid
|
425 |
130K |
29 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
425
|
130K
|
29
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
TheSanDiegoKid
|
377 |
145K |
22 |
21/06/22 |
21/06/22 |
ASX - By Stock
|
377
|
145K
|
22
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
TheSanDiegoKid
|
377 |
145K |
3 |
20/06/22 |
20/06/22 |
ASX - By Stock
|
377
|
145K
|
3
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Investor Webinar
|
|
TheSanDiegoKid
|
118 |
39K |
3 |
18/06/22 |
18/06/22 |
ASX - By Stock
|
118
|
39K
|
3
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
TheSanDiegoKid
|
377 |
145K |
19 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
377
|
145K
|
19
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
TheSanDiegoKid
|
377 |
145K |
6 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
377
|
145K
|
6
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Increased Scheme Consideration from Pfizer
|
|
TheSanDiegoKid
|
377 |
145K |
32 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
377
|
145K
|
32
|
|
ASX - By Stock
|
RAP |
Re:
RAP media thread.
|
|
TheSanDiegoKid
|
3.3K |
2.5M |
11 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
3.3K
|
2.5M
|
11
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Voluntary Suspension Extension
|
|
TheSanDiegoKid
|
92 |
44K |
4 |
09/06/22 |
09/06/22 |
ASX - By Stock
|
92
|
44K
|
4
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Voluntary Suspension Extension
|
|
TheSanDiegoKid
|
88 |
41K |
5 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
88
|
41K
|
5
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Voluntary Suspension Extension
|
|
TheSanDiegoKid
|
88 |
41K |
15 |
08/06/22 |
08/06/22 |
ASX - By Stock
|
88
|
41K
|
15
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Voluntary Suspension Extension
|
|
TheSanDiegoKid
|
88 |
41K |
48 |
06/06/22 |
06/06/22 |
ASX - By Stock
|
88
|
41K
|
48
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Suspension from Official Quotation
|
|
TheSanDiegoKid
|
128 |
52K |
8 |
02/06/22 |
02/06/22 |
ASX - By Stock
|
128
|
52K
|
8
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Trading Halt
|
|
TheSanDiegoKid
|
98 |
46K |
25 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
98
|
46K
|
25
|
|
ASX - By Stock
|
RAP |
Re:
RAP media thread.
|
|
TheSanDiegoKid
|
3.3K |
2.5M |
0 |
12/05/22 |
12/05/22 |
ASX - By Stock
|
3.3K
|
2.5M
|
0
|
|
ASX - By Stock
|
RAP |
Re:
Ann: Quarterly Activities Report and Appendix 4C
|
|
TheSanDiegoKid
|
98 |
38K |
19 |
27/04/22 |
27/04/22 |
ASX - By Stock
|
98
|
38K
|
19
|
|
ASX - By Stock
|
RAP |
Re:
RAP media thread.
|
|
TheSanDiegoKid
|
3.3K |
2.5M |
12 |
20/04/22 |
20/04/22 |
ASX - By Stock
|
3.3K
|
2.5M
|
12
|
|
ASX - By Stock
|
RAP |
Re:
RAP media thread.
|
|
TheSanDiegoKid
|
3.3K |
2.5M |
10 |
20/04/22 |
20/04/22 |
ASX - By Stock
|
3.3K
|
2.5M
|
10
|
|
ASX - By Stock
|
RAP |
Re:
Vote NO Pfizer offer
|
|
TheSanDiegoKid
|
555 |
192K |
8 |
13/04/22 |
13/04/22 |
ASX - By Stock
|
555
|
192K
|
8
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResApp announces positive results of COVID-19 screening test
|
|
TheSanDiegoKid
|
530 |
153K |
23 |
04/04/22 |
04/04/22 |
ASX - By Stock
|
530
|
153K
|
23
|
|
ASX - By Stock
|
RAP |
Re:
Ann: ResApp announces positive results of COVID-19 screening test
|
|
TheSanDiegoKid
|
530 |
153K |
2 |
22/03/22 |
22/03/22 |
ASX - By Stock
|
530
|
153K
|
2
|
|